Corvas starts Phase IIb study in stroke

CVAS partner Pfizer (PFE) began Phase IIb testing of UK-279,276 (recombinant neutrophil inhibitory factor) to treat acute stroke. The dose-ranging study will examine functional and neurological outcom...